{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:07:12Z","timestamp":1788836832024,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010566","name":"Consejer\u00eda de Salud, Junta de Andaluc\u00eda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010566","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009574","name":"Servicio Murciano de Salud","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009574","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010198","name":"Ministerio de Econom\u00eda, Industria y Competitividad, Gobierno de Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI16\/01443"],"award-info":[{"award-number":["PI16\/01443"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI15\/01607"],"award-info":[{"award-number":["PI15\/01607"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI15\/00713"],"award-info":[{"award-number":["PI15\/00713"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["Programa-I3SNS"],"award-info":[{"award-number":["Programa-I3SNS"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.jhep.2019.02.018","type":"journal-article","created":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T21:20:49Z","timestamp":1551993649000},"page":"45-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy"],"prefix":"10.1016","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4778-790X","authenticated-orcid":false,"given":"Juan","family":"Mac\u00edas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis E.","family":"Morano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"T\u00e9llez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Granados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5813-6889","authenticated-orcid":false,"given":"Antonio","family":"Rivero-Ju\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00aaJos\u00e9","family":"R\u00edos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"P\u00e9rez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Collado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Figueruela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aitana","family":"Morano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Freyre-Carrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7611-781X","authenticated-orcid":false,"given":"Federico","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3751-0296","authenticated-orcid":false,"given":"Juan A.","family":"Pineda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2019.02.018_b0005","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrgastro.2013.107","article-title":"Epidemiology and natural history of HCV infection","volume":"10","author":"Hajarizadeh","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2019.02.018_b0010","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.antiviral.2014.01.002","article-title":"Can hepatitis C virus infection be eradicated in people who inject drugs?","volume":"104","author":"Grebely","year":"2014","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jhep.2019.02.018_b0015","doi-asserted-by":"crossref","first-page":"S304","DOI":"10.1086\/427445","article-title":"Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users","volume":"40","author":"Strathdee","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2019.02.018_b0020","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1093\/cid\/cit305","article-title":"Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study","volume":"57","author":"Alavi","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2019.02.018_b0025","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/jvh.12129","article-title":"Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999\u20132011","volume":"21","author":"Iversen","year":"2014","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2019.02.018_b0030","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/liv.12370","article-title":"Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents","volume":"34","author":"Alavi","year":"2014","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2019.02.018_b0035","unstructured":"AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. http:\/\/www.hcvguidelines.org. [Accessed in January 2017]. 2017."},{"key":"10.1016\/j.jhep.2019.02.018_b0040","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"EASL Recommendations on Treatment of Hepatitis C 2016","volume":"66","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.02.018_b0045","doi-asserted-by":"crossref","first-page":"215","DOI":"10.7326\/M15-0406","article-title":"Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States","volume":"163","author":"Barua","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2019.02.018_b0050","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3109\/10826084.2016.1161054","article-title":"Clinicians' views of hepatitis C virus treatment candidacy with direct-acting antiviral regimens for people who inject drugs","volume":"51","author":"Asher","year":"2016","journal-title":"Subst Use Misuse"},{"key":"10.1016\/j.jhep.2019.02.018_b0055","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/cid\/civ1222","article-title":"How generalizable are the results from trials of direct antiviral agents to people coinfected With HIV\/HCV in the real world?","volume":"62","author":"Saeed","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2019.02.018_b0060","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2019.02.018_b0065","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Feld","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2019.02.018_b0070","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2019.02.018_b0075","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jhep.2015.03.029","article-title":"Ombitasvir\/paritaprevir\/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine","volume":"63","author":"Lalezari","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.02.018_b0080","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/M16-0816","article-title":"Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial","volume":"165","author":"Dore","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2019.02.018_b0085","doi-asserted-by":"crossref","DOI":"10.1038\/nrgastro.2017.106","article-title":"Direct-acting antiviral agents for HCV infection affecting people who inject drugs","author":"Grebely","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2019.02.018_b0090","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S2468-1253(17)30404-1","article-title":"Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial","volume":"3","author":"Grebely","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2019.02.018_b0095","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1093\/infdis\/jis928","article-title":"Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV\/HIV coinfection: action required at the system, provider, and patient levels","volume":"207","author":"Grebely","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2019.02.018_b0100","unstructured":"Strategic Plan for Tackling Hepatitis C in the Spanish National Health System 2015."},{"key":"10.1016\/j.jhep.2019.02.018_b0105","unstructured":"Gu\u00edas AEEH\/SEIMC de manejo de la Hepatitis C. 2017; Available at: http:\/\/seimc.org\/contenidos\/gruposdeestudio\/gehep\/dcientificos\/documentos\/gehep-dc-2017-ManejoHepatitisC-AEEHySEIMC-Marzo.pdf."},{"key":"10.1016\/j.jhep.2019.02.018_b0110","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/hep4.1050","article-title":"Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: a systematic review","volume":"1","author":"Bartlett","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2019.02.018_b0115","doi-asserted-by":"crossref","unstructured":"Cuypers L, P\u00e9rez AB, Chueca N, Aldamiz-Echevarria T, Alados J, Martinez-Sapina A, et al. Relapse or reinfection of hepatitis C after direct acting antiviral treatment: unraveled by phylogenetic analysis. Results from the Spanish GEHEP-004 cohort. International Workshop on HIV and Hepatitis Co-infection edition:13. Lisbon, Portugal; 2017.","DOI":"10.1371\/journal.pone.0201268"},{"key":"10.1016\/j.jhep.2019.02.018_b0120","doi-asserted-by":"crossref","DOI":"10.1111\/add.14128","article-title":"Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?","author":"Christensen","year":"2018","journal-title":"Addiction"},{"key":"10.1016\/j.jhep.2019.02.018_b0125","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/cid\/ciw806","article-title":"From care to cure: demonstrating a model of clinical patient navigation for hepatitis C care and treatment in high-need patients","volume":"64","author":"Ford","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2019.02.018_b0130","unstructured":"Ward K, Falade-Nwulia O, Moon J, Sutcliffe C, Brinkley S, Haselhuhn T, et al. Randomized controlled trial of cash incentives or peer mentors to improve HCV linkage and treatment among HIV\/HCV coinfected persons who inject drugs: the CHAMPS study AASLD: the Liver Meeting\u00ae 2017, October 20\u201324, 2017. Washington, DC; 2017."},{"key":"10.1016\/j.jhep.2019.02.018_b0135","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1080\/15284336.2017.1330801","article-title":"HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study","volume":"18","author":"Neukam","year":"2017","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.jhep.2019.02.018_b0140","doi-asserted-by":"crossref","first-page":"ofx158","DOI":"10.1093\/ofid\/ofx158","article-title":"Liver cirrhosis as a risk factor for direct-acting antiviral therapy failure in real-life hepatitis C virus\/human immunodeficiency virus coinfection","volume":"4","author":"Boesecke","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jhep.2019.02.018_b0145","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1097\/QAD.0000000000001042","article-title":"Directly acting antivirals for hepatitis C virus arrive in HIV\/hepatitis C virus co-infected patients: from 'mind the gap' to 'where's the gap?'","volume":"30","author":"Childs","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2019.02.018_b0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161821","article-title":"Limited generalizability of registration trials in hepatitis C: a nationwide cohort study","volume":"11","author":"Berden","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2019.02.018_b0155","unstructured":"Naggie S, Rosenthal E, Kattakuzhy S, McGinnis J, Serrao R, Silva-Pinto A, et al. Real world effectiveness of ledipasvir\/sofosbuvir in patients coinfected with HCV and HIV-1: a comparative analysis of clinical trials with four real world cohorts AASLD. Boston, MA. 2016 Nov 11\u201315; 2016."},{"key":"10.1016\/j.jhep.2019.02.018_b0160","unstructured":"Boesecke C, Ingiliz P, Berger F, Lutz T, Schewe K, Wiesch JS, et al. Same same but different? Risk of DAA therapy failure in real-life HCV\/HIV coinfection. CROI. Seattle, Washington. February 13\u201316, 2017"},{"key":"10.1016\/j.jhep.2019.02.018_b0165","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1473-3099(16)30408-X","article-title":"Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study","volume":"17","author":"Deterding","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2019.02.018_b0170","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S2468-1253(17)30003-1","article-title":"Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial","volume":"2","author":"Rockstroh","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827819301333?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827819301333?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:54:22Z","timestamp":1777510462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827819301333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0168827819301333"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2019.02.018","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2019.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}